Background {#Sec1}
==========

Although nowadays healthcare systems are largely configured to manage individual diseases rather than multimorbidity, there is an increasing awareness of the importance of comorbidities in patients with chronic conditions \[[@CR1]\]. Chronic obstructive pulmonary disease (COPD), a prevalent chronic respiratory condition, is a major cause of morbidity and mortality worldwide \[[@CR2]\]. In the past decade several studies have shown that COPD often coexists with other diseases, \[[@CR3], [@CR4]\] and that comorbidity is associated with poorer clinical outcomes \[[@CR4], [@CR5]\]. Some of these comorbidities arise independently of COPD, whereas others may be causally related, either through shared risk factors (smoking, aging) or shared pathophysiology, as a complication of COPD, or due to medication side effects.

Several associations between COPD and particular comorbidities have been shown. Cardiovascular disease, metabolic syndrome, skeletal muscle dysfunction, osteoporosis, depression and lung cancer are all highly prevalent among patients with any severity of COPD, and cross-sectional studies have shown their significant impact on patients' health-related quality of life \[[@CR2], [@CR6], [@CR7]\]. Most of the research on comorbidity in COPD comes from studies in secondary care populations, thus representing patients in the more severe part of the COPD severity spectrum \[[@CR4]\]. However, in most developed countries, the vast majority of patients with COPD are managed in primary care. Studies performed in general practice settings report that 21 to 74% of patients with COPD suffer from two or more additional chronic diseases \[[@CR6], [@CR8]\].

As COPD is a progressive disease, factors that influence its prognosis are important to consider when managing patients. Since exacerbation frequency is a known predictor of COPD progression, \[[@CR2]\] it is important to know what the potential impact of comorbidities on the risk of exacerbations is. Recently Putcha et al*.*reported a model in which the number of comorbid conditions predicted dyspnea and exacerbation risk \[[@CR9]\]. This prediction model does, however, not take into account which particular comorbid conditions are associated with exacerbation risk. Other previous studies have predominantly looked at mortality as the outcome of interest, \[[@CR5], [@CR10], [@CR11]\] but from a patient management perspective it is important that physicians consider comorbidities that influence potentially modifiable prognostic factors like exacerbation rate in their treatment decisions. Therefore, the aim of the current study was to explore associations between a wide range of comorbid chronic conditions and exacerbation risk in a real-life cohort of primary care patients with COPD.

Methods {#Sec2}
=======

Design and dataset {#Sec3}
------------------

The study used routine data from a general practice database from the Department of Primary and Community Care at the Radboud University Medical Center, Nijmegen, the Netherlands. De-identified electronic medical records from primary care patients diagnosed with COPD from 179 general practices in the eastern part of the Netherlands were available in the database.

For each registered subject, the following data were extracted: age, sex, all diagnoses using the International Classification of Primary Care (ICPC), extended with Dutch ICPC sub-codes, \[[@CR12]\] and all prescribed medication. ICPC-2 or ICD10 coding data were recoded into ICPC-1. Medication prescriptions (i.e., prescription start and end dates, dosage, frequency, and duration) were extracted and categorized using the Anatomical Therapeutic Chemical (ATC) classification system \[[@CR13]\]. For the current study only the data on prescriptions for oral corticosteroids were used.

Study population {#Sec4}
----------------

Subjects aged ≥40 years were included in the study population when they had physician-diagnosed COPD (as labeled with ICPC code R95 in the electronic medical record) before or during the study period. Asthma (ICPC R96) in addition to the COPD code was not an exclusion criterion. The follow-up period covered the years 2012 and 2013. The observation period for patients terminated either at the end of the study period (31 December 2013), or when a subject died or deregistered from the practice.

Comorbidities {#Sec5}
-------------

The selection of chronic comorbid diseases studied was based on existing literature \[[@CR1], [@CR14]\], the authors' clinical expertise and expert opinions (Nielen MM, Spronk I, Davids R, Korevaar JC, Poos MJ, Hoeymans N, Opstelten W, van der Sande MAB, Biermans MCJ, Schellevis FG, RA V: A new method for estimating morbidity rates based on routine electronic medical records in primary care, submitted). We considered all chronic diseases as comorbidities, regardless whether the disease had been diagnosed before the COPD diagnosis or thereafter. Apart from all 'obligatory' chronic diseases we also included several recurrent diseases (i.e., depression, anxiety, anemia, dyspepsia, urinary tract infection) which could potentially influence COPD outcomes. After reaching consensus about these recurrent comorbidities within the research team, ICPC (sub)codes were linked (see [Appendix 1](#Sec17){ref-type="sec"}). Selection of the recurrent comorbidities in our population was based on the patient's history in terms of these particular ICPC codes. To define whether a history of ICPC codes was relevant or irrelevant for the aim of the study, we added specific selection criteria based on published clinical guidelines for the respective diseases (see [Appendix 1](#Sec17){ref-type="sec"}).

Finally, a total of 82 chronic comorbid conditions were selected and included in the analyses. The comorbidities were clustered and analyzed based on their ICPC codes into the following 14 categories: respiratory; cardiovascular; digestive; endocrine; metabolic/nutrition; musculoskeletal; neurologic; psychiatric; urogenital; blood (−forming organs)/lymphatics; infectious; eye/ear/skin; non-pulmonary cancer; and pulmonary cancer. Low prevalence categories were merged (see [Appendix 2](#Sec18){ref-type="sec"}). To restrict ourselves, we focused on conditions with a high prevalence and cardiopulmonary comorbidities (other than COPD) with a lower prevalence (7 conditions, see Table [2](#Tab2){ref-type="table"}). High-prevalent comorbidities (19 conditions), further referred to as 'frequent comorbidities', were defined as being present in ≥5% of the study population. This resulted in a total of 26 comorbidities remaining for further analyses.

Outcomes {#Sec6}
--------

The outcomes for the study were (i) prevalence of comorbidities in the study population, (ii) annual rate of exacerbations (dichotomized as \<2 *versus* ≥2 exacerbations/year based on the cumulated 2012/13 data), and (iii) time (in days) until first exacerbation. An exacerbation was defined as a prescription of oral corticosteroids (i.e., prednisolone (ATC H02AB06) or prednisone (ATC H02AB07)) with a minimum daily dose of 20 mg for a minimum duration of 5 days and a maximum duration of 15 days (based on Dutch GP guidelines for treatment of COPD exacerbations \[[@CR15]\]). As there is no consensus in the literature regarding a cut-off to differentiate between relapse of an earlier exacerbation and a new exacerbation, \[[@CR16]\] we considered a subsequent predniso(lo)ne prescription after an oral corticosteroid-free interval of ≥14 days since the end-date of the previous prescription as a new exacerbation.

Statistical analysis {#Sec7}
--------------------

Analyses were performed with SPSS statistical software (version 22, IBM SPSS Statistics, Feltham, Middlesex, UK) and Microsoft Excel 2007 (Microsoft Corporation, Redmond, Washington, US). Statistically significant results were defined as *p* \< 0 · 05. Patients' baseline characteristics and comorbidity prevalence rates were calculated. We performed Chi-square tests for categorized variables and independent t-tests for continuous variables to analyze differences between the subgroups with \<2 and ≥2 exacerbations per year.

We explored associations between comorbidities and exacerbation risk using univariable analyses. Hazard ratios for comorbidities were calculated using Cox regression, in which the time variable consisted of time to the first exacerbation. Data from patients who died or were otherwise lost to follow up were right-censored. Subsequently, all frequent and cardiopulmonary comorbidities (Table [2](#Tab2){ref-type="table"}), age, and gender were included as covariates in multivariate Cox regression analyses. The model was reduced through backward exclusion to produce a final model that consisted of only non-collinear, independently associated, statistically significant covariates. The same modeling approach was used for comorbidity categories using all other categories, with age and gender as covariates.

In addition, we performed multivariable logistic regression analyses to calculate odds ratio's (ORs) with the dichotomous indicator variable for exacerbation frequency (\<2 *versus* ≥2 exacerbations/year) as the dependent variable. Predictor variables in the logistic models were: all frequent comorbidities, all cardiopulmonary comorbidities, gender, and age. This modeling approach was also used to analyze the 14 categories of comorbidity.

Results {#Sec8}
=======

Study population {#Sec9}
----------------

Overall, data of 16,427 subjects diagnosed with COPD were available for analyses. Of these patients, 1824 (11 · 1%) were lost to follow-up during the 2-year study period. Reason for loss to follow-up was known for 800 (44 · 5%) of these patients, with death being the predominant reason. Table [1](#Tab1){ref-type="table"} shows baseline characteristics of the patients with complete follow-up (i.e., the final study population, *n* = 14,603). Mean (SD) age was 66 · 5 (11 · 5) years and 53% were males. At baseline, 89 · 1% of patients suffered from ≥1 chronic comorbid conditions, while 23 · 1% had ≥5 comorbidities. Most prevalent comorbid conditions were hypertension (35 · 2%), coronary heart disease (19 · 2%), osteoarthritis (17 · 6%), diabetes (17 · 3%), and peripheral vascular disease (14 · 3%). Table [2](#Tab2){ref-type="table"} shows the prevalence rates of the frequent and cardiopulmonary comorbidities. Table [3](#Tab3){ref-type="table"} shows the prevalence of ICPC-categorized comorbidities.Table 1Baseline characteristics of the COPD study population grouped by low (\<2/year) *versus* high (≥2/year) exacerbation ratePatients with full follow-up (study population)^a^\
(*n* = 14,603)Subgroups of study populationPatient characteristicsPatients with \<2 exacerbations/year (*n* = 13,709)Patients with ≥2 exacerbations/year (*n* = 894)^b^Sex, male, n (%)7,749 (53 · 1)7,322 (53 · 4)427 (47 · 8)^‡^Age at study baseline, years; mean (SD; range)66 · 5 (11 · 5; 40--110)^‡^66 · 5 (11 · 6; 40--110)67 · 4 (10 · 3; 40--93)^‡^Full dataset available (censored data), n (%) Full data available13,709 (93 · 9)894 (6 · 1) DeceasedN/AN/AN/A MovedN/AN/AN/A Nursing homeN/AN/AN/A UnknownN/AN/AN/AComorbidity dataNumber of comorbid diseases^c^, mean (SD; range)3 · 0 (2 · 3;0--20)^‡^3 · 0 (2 · 3;0--16)3 · 4 (2 · 5; 0--20)^‡^Number of comorbid diseases categories^c^, n (%) 01,777 (12 · 2)1,700 (12 · 4)77 (8 · 6) 1 or 25,305 (36 · 6)5,021 (36 · 6)284 (31 · 8) 3 or 44,258 (29 · 2)3,977 (29 · 0)281 (31 · 4) 5 and more3,263 (22 · 3)^‡^3,011 (22 · 0)252 (28 · 2)^‡^ExacerbationsNumber of exacerbations^d^, mean (SD; range)0 · 75 (1 · 5;0--15)^‡^0 · 44 (0 · 8;0--2)5 · 6 (2 · 0;3--15)^‡^*SD* standard deviation, *N/A* not applicable^\*^ *p* \< 0.05, ^†^ *p* \< 0.01, ^‡^ *p* \< 0.001^a^ *p*-values displayed are calculated for the difference between patients lost to follow-up *versus* patients with full follow-up. Chi-square tests for categorized variables and independent t-tests for continuous variables. *p* \< 0 · 05 was considered statistically significant^b^ *p*-values displayed are calculated for the difference between the subgroups \<2 *versus* ≥2 exacerbations/year. Chi-square tests for categorized variables and independent t-tests for continuous variables. *p* \< 0 · 05 was considered statistically significant^c^presence of any type of comorbid disease was assessed at study baseline, i.e., 1 January 2012^d^Mean number of exacerbations during the study period, 1 January 2012 -- 31 December 2013Baseline characteristics of the initial population of all COPD patients (*n* = 16,427) and those who were lost to follow-up (*n* = 1,824) are reported in [Appendix 3](#Sec19){ref-type="sec"} Table 2Prevalence of frequent and cardiopulmonary comorbidity in the study population, sorted from highest to lowest prevalence rateTotal study population^a^, (*n* = 14,603)Patients with \<2 exacerbations/year, (*n* = 13,709)Patients with ≥2 exacerbations/year, (*n* = 894)*p*-value^b^Frequent comorbidity Hypertension5,116 (35 · 0)4,805 (35 · 2)311 (34 · 8)0 · 873 Coronary heart disease2,759 (18 · 9)2,569 (18 · 7)191 (21 · 4)0 · 051 Osteoarthritis2,570 (17 · 6)2,402 (17 · 5)168 (18 · 8)0 · 334 Diabetes2,464 (16 · 9)2,330 17 · 0)134 (15 · 0)0 · 120 Peripheral vascular disease2,031 (13 · 9)1,897 (14 · 8)150 (16 · 8)*0 · 006* Blindness & low vision1,938 (13 · 3)1,772 (12 · 9)166 (18 · 6)*\<0 · 001* Dyspepsia, gastroesophageal reflux1,845 (12 · 6)1,703 (12 · 4)142 (15 · 9)*0 · 003* Dislipidemia1,703 (11 · 7)1,613 (11 · 8)90 (10 · 1)0 · 125 Stroke & transient ischaemic attack1,357 (9 · 3)1,259 (9 · 2)98 (11 · 0)0 · 076 Chronic kidney diease1,360 (9 · 3)1,263 (9 · 2)97 (10 · 9)0 · 103 Asthma1,305 (8 · 9)1,202 (8 · 8)103 (11 · 5)*0 · 005* Hearing loss1,144 (7 · 8)1,078 (7 · 9)66 (7 · 4)0 · 604 Heart failure1,048 (7 · 2)943 (6 · 9)105 (11 · 7)*\<0 · 001* Atrial fibrillation1,044 (7 · 1)964 (7 · 0)80 (8 · 9)0 · 031 Skin cancer913 (6 · 3)862 (6 · 3)51 (5 · 7)0 · 485 Osteoporosis/osteopenia884 (6 · 1)801 (5 · 8)83 (9 · 3)*\<0 · 001* Thyroid disorder808 (5 · 5)757 (5 · 5)51 (5 · 9)0 · 817 Depression800 (5 · 5)729 (5 · 3)71 (7 · 9)*0 · 001* Prostate disorders784 (5 · 4)719 (5 · 2)65 (7 · 3)*0 · 009*Cardiopulmonary comorbidity Heart valve disease568 (3 · 9)528 (3 · 9)40 (7 · 8)*0 · 035* Bronchiectasis/chronic bronchitis414 (2 · 8)379 (2 · 8)35 (3 · 9)0 · 045 Pulmonary cancer317 (2 · 2)284 (2 · 1)33 (3 · 7)*0 · 001* Sleep apneu syndrome173 (1 · 2)161 (1 · 2)12 (1 · 3)0 · 653 Other chronic pulmonary disease157 (1 · 1)148 (1 · 1)9 (1 · 0)0 · 838 Recurrent sinusitis54 (0 · 4)49 (0 · 4)55 (6 · 2)0 · 335 Congenital cardiovascular anomaly32 (0 · 2)28 (0 · 2)4 (0 · 4)0 · 132^a^COPD population with complete data available, patients lost to follow-up (*n* = 1,824) excluded^b^ *p*-values displayed are calculated for the difference between the subgroup \<2 *versus* ≥2 exacerbations/year Chi-square tests for categorized variables. *p* \< 0 · 05 was considered statistically significant Table 3Prevalence of ICPC-categorized comorbidity in the COPD study population, sorted from highest to lowest prevalence rate of frequent exacerbationsStudy population^a^, (*n* = 14,603)Patients with \<2 exacerbations/year, (*n* = 13,709)Patients with ≥2 exacerbations/year (*n* = 894)*p*-value^b^Comorbidity category Cardiovascular8,516 (58 · 3)7,955 (58 · 0)561 (62 · 8)0 · 006 Endocrine, metabolic and nutrition4,856 (33 · 3)4,568 (33 · 3)288 (25 · 5)0 · 496 Musculoskeletal3,588 (24 · 6)3,337 (24 · 3)251 (28 · 1)0 · 012 Eye and ear2,984 (20 · 4)2,762 (20 · 1)222 (24 · 8)0 · 001 Digestive2,801 (19 · 2)2,597 (18 · 9)204 (22 · 8)0 · 004 Urogenital (male and female)2,330 (16 · 0)2,146 (15 · 7)184 (20 · 6)\<0 · 001 Psychiatric2,271 (15 · 6)2,092 (15 · 3)179 (20 · 0)\<0 · 001 Non-pulmonary cancer2,203 (15 · 1)2,071 (15 · 1)132 (14 · 8)0 · 782 Respiratory (excl · pulmonary cancer)1,998 (13 · 7)1,839 (13 · 4)159 (17 · 8)\<0 · 001 Skin1,395 (9 · 6)1,314 (9 · 6)81 (9 · 1)0 · 605 Neurological413 (2 · 8)389 (2 · 8)24 (2 · 7)0 · 789 Pulmonary cancer317 (2 · 2)284 (2 · 1)33 (3 · 7)0 · 001 Blood (forming organs) and lymphatics106 (0 · 7)97 (0 · 7)9 (1 · 0)0 · 307 Infectious87 (0 · 6)80 (0 · 6)7 (0 · 8)0 · 453*ICPC* International Classification of Primary Care^a^Total COPD population, with patients who were lost to follow-up (*n* = 1,824) excluded^b^ *p*-values displayed are calculated for the difference between the group \<2 *versus* ≥2 exacerbations/year. We performed Chi-square tests for categorized variables. *p*-value \<0 · 05 was considered statistically significant

During the 2-year study period the mean number of exacerbations per patient was 0.72 (SD 1 · 5). 68% of patients had no exacerbation and 5 · 7% had ≥4 exacerbations during the study period.

Associations between comorbidities and exacerbation frequency {#Sec10}
-------------------------------------------------------------

Tables [2](#Tab2){ref-type="table"} and [3](#Tab3){ref-type="table"} show the univariable associations between comorbidities and comorbidity categories and the exacerbation frequency subgroups, respectively. Overall, patients with one or more comorbid conditions more often had ≥2 exacerbations/year compared to patients without any comorbidity (5 · 9% *vs* 4 · 0%, *p* = 0 · 001). Patients with any other chronic respiratory disease next to their COPD, (*n* = 2,294, 15 · 7%) more often had ≥2 exacerbations per year compared to patients without respiratory comorbidity (8 · 2% vs 5 · 7%, *p* \< 0 · 001).

Univariable logistic regression analysis showed that COPD patients with pulmonary cancer had 1.81 higher odds for ≥2 exacerbations per year compared to patients without pulmonary cancer (Fig. [1](#Fig1){ref-type="fig"}, *p* = 0.002). Patients who, next to their COPD, also suffered from asthma, blindness or low vision, coronary heart disease, depression, dyspepsia, heart failure, osteoporosis or osteopenia, peripheral vascular disease, or prostate disorders, had a higher risk of having frequent exacerbations compared to those who did not suffer from these comorbid conditions (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Comorbidome of comorbidities in the COPD study population (*n* = 14,603). Results are from univariable (upper panel) and multivariable (lower panel, corrected for age, gender and the other comorbidities) logistic regression analysis. (Diameter of the coloured circles represents the prevalence of each comorbidity. Proximity to the black centre of the circle represents stronger positive association (OR) with ≥2 exacerbation per year. The dashed circle represents an OR of 1. Comorbidities marked **bold** were statistically significantly (i.e., *p* \< 0.05) associated with increased or decreased risk. In the multivariable model covariates were sequentially dropped until only statistically significant covariates remained. Comorbidities outside the dashed circle were negatively associated (i.e., 'protective') with ≥2 exacerbation/year. Comorbidities with prevalence \<5% were not analysed). CKD: chronic kidney disease. COPD: chronic obstructive pulmonary disease. GERD: gastroesophageal reflux disease. TIA: transient ischemic attack

Table [4](#Tab4){ref-type="table"} lists the comorbidities and comorbidity categories significantly associated with having ≥2 exacerbation per year. In the multivariable logistic regression analysis, among the statistically significant associations, the highest ORs for having ≥2 exacerbations per year were observed for pulmonary cancer (OR 1 · 85; 95% CI 1 · 28--2 · 67), heart failure (OR 1 · 72; 1 · 38--2 · 14), prostate disorders (OR 1 · 50; 1 · 13--1 · 98) and blindness/low vision (OR 1 · 46; 1 · 21--1 · 75) as comorbid conditions (Table [4](#Tab4){ref-type="table"}). Dislipidemia was not statistically significant, but did show a trend, with an OR of 0 · 81 (95% CI 0 · 65--1 · 01, *p* = 0 · 071). When looking at comorbidity categories, patients with other chronic respiratory conditions (OR 1 · 37; 1 · 15--1 · 64) and psychiatric comorbidities (OR 1 · 35; 1 · 13--1 · 60) were at highest risk for frequent exacerbations.Table 4Comorbidities associated with ≥2 exacerbations/year versus \<2 exacerbations/year in COPD patients, corrected for age and sex (multivariable results), sorted by *p*-valueOdds ratio (95%CI)*p*-valueComorbid conditions^a,\ b^ Heart failure1 · 72 (1 · 38--2 · 14)\<0 · 001 Blindness & low vision1 · 46 (1 · 21--1 · 75)\<0 · 001 Pulmonary cancer1 · 85 (1 · 28--2 · 67)0 · 002 Depression1 · 48 (1 · 14--1 · 91)0 · 003 Prostate disorders1 · 50 (1 · 13--1 · 98)0 · 004 Asthma1 · 36 (1 · 11--1 · 70)0 · 004 Osteoporosis/osteopenia1 · 41 (1 · 11--1 · 80)0 · 006 Diabetes0 · 80 (0 · 66--0 · 97)0 · 020 Dyspepsia, gastroesophageal reflux1 · 25 (1 · 03--1 · 50)0 · 023 Peripheral vascular disease1 · 20 (1 · 00--1 · 45)0 · 049Comorbidity categories^b,c^ Respiratory (excl. pulmonary cancer)1 · 37 (1 · 15--1 · 64)\<0 · 001 Psychiatric1 · 35 (1 · 13--1 · 60)\<0 · 001 Urogenital (male and female)1 · 34 (1 · 12--1 · 60)\<0 · 001 Eye and ear1 · 25 (1 · 06--1 · 47)0 · 007 Endocrine, metabolic and feeding0 · 85 (0 · 73--0 · 99)0 · 032 Cardiovascular1 · 17 (1 · 01--1 · 36)0 · 037*OR* odds ratio^a^All chronic comorbidities with prevalence ≥5% and cardiopulmonary comorbidities were included in the multivariable logistic regression model^b^Reference category was 'comorbidity not diagnosed before study period' (i.e., 1 January 2012)^c^All ICPC comorbidity categories were included in the multivariate logistic regression mode

Time to first exacerbation {#Sec11}
--------------------------

Table [5](#Tab5){ref-type="table"} summarizes the results from the Cox regression analyses. Among the statistically significant associations, the comorbid conditions with the highest risk of developing a first exacerbation were recurrent sinusitis (Cox hazard ratio 1 · 53; 95% CI, 1 · 05--2 · 24), bronchiectasis/chronic bronchitis (HR = 1.50; 1.31--1.73) and heart failure (1 · 41; 1 · 29--1 · 55). For dislipidemia a non-statistically HR of 0 · 92 was observed (*p* = 0 · 067, 95% CI 0 · 85--1 · 00).Table 5Comorbidities associated with development of a first exacerbation in the study population, corrected for age and sex (results from multivariable Cox regression analysis), sorted by *p*-valueCox hazard ratio (95% CI)*p*-valueComorbidity^a,b^ Bronchiectasis/chronic bronchitis1 · 50 (1 · 31--1 · 73)\<0 · 001 Heart failure1 · 41 (1 · 29--1 · 55)\<0 · 001 Depression1 · 34 (1 · 20--1 · 50)\<0 · 001 Atrial fibrillation1 · 27 (1 · 16--1 · 40)\<0 · 001 Asthma1 · 24 (1 · 14--1 · 36)\<0 · 001 Peripheral vascular disease1 · 15 (1 · 07--1 · 24)\<0 · 001 Prostate disorders1 · 20 (1 · 04--1 · 45)0 · 002 Blindness & low vision1 · 11 (1 · 03--1 · 20)0 · 009 Coronary heart disease1 · 10 (1 · 02--1 · 17)0 · 011 Dyspepsia, gastroesophageal reflux1 · 10 (1 · 02--1 · 20)0 · 013 Pulmonary cancer1 · 23 (1 · 04--1 · 45)0 · 016 Recurrent sinusitis1 · 53 (1 · 05--2 · 24)0 · 028 Osteoporosis/osteopenia1 · 12 (1 · 01--1 · 25)0 · 037Comorbidity category^b,\ c^ Respiratory (excl. pulmonary cancer)1 · 26 (1 · 17--1 · 36)\<0 · 001 Urogenital (male and female)1 · 18 (1 · 10--1 · 27)\<0 · 001 Cardiovascular1 · 16 (1 · 08--1 · 24)\<0 · 001 Mental health1 · 16 (1 · 08--1 · 24)\<0 · 001 Eye and ear1 · 09 (1 · 02--1 · 16)0 · 013 Digestive1 · 07 (1 · 00--1 · 15)0 · 042^a^All chronic comorbidities with prevalence ≥5% and cardiopulmonary comorbidities were included in the multivariate Cox regression model^b^Reference category was 'comorbidity not diagnosed before study period' (i.e., 1 January, 2012)^c^All ICPC comorbidity categories were included in the multivariate Cox regression model

Having another chronic respiratory disease beside COPD was also associated with risk of developing a first exacerbation (Cox hazard ratio 1 · 26; 1 · 17--1 · 36), see Fig. [2](#Fig2){ref-type="fig"}.Fig. 2Hazard for exacerbation split by COPD patients with versus without one or more diagnoses of other chronic respiratory diseases at baseline. (Patients with another chronic respiratory disease next to their COPD showed a higher hazard rate for the development of a first exacerbation (Cox hazard ratio 1.26; 1.17--1.36) compared to patients without another chronic respiratory disease). COPD: chronic obstructive pulmonary disease

Discussion {#Sec12}
==========

In this paper we explored the prevalence of comorbid chronic conditions and associations with exacerbation risk in a real-life cohort of primary care COPD patients. Our findings support the notion that comorbidities are rather rule than exception in patients with COPD \[[@CR4]\], with 88% having at least one other chronic disease. Several comorbidities were associated with having frequent exacerbations, with heart failure, blindness/low vision and pulmonary cancer showing the strongest associations in terms of statistical significance. In contrast, diabetes was associated with a lower risk of having frequent exacerbations. Bronchiectasis/chronic bronchitis, heart failure and depression were the strongest predictors for developing a new exacerbation.

Comparison with existing literature {#Sec13}
-----------------------------------

Previous research has shown that cardiovascular, psychiatric, and metabolic comorbidity are highly prevalent in COPD patients, \[[@CR8], [@CR17]\] and our results confirm these findings. In addition to the finding by Rutten et al*.* \[[@CR18]\] that unrecognized heart failure is rather common in elderly patients with stable COPD, our data also indicate that heart failure may increase the risk of having frequent exacerbations. Recent clinical trial data have shown correlations between several comorbidities and mortality risk if a COPD patient is admitted to hospital with an acute exacerbation \[[@CR19], [@CR20]\]. Our observations support the association between chronic comorbidity and exacerbation risk in a primary care study population, i.e., the COPD population without selection of any kind, which is unprecedented and impossible to derive from clinical trial populations \[[@CR21]\].

We observed a trend towards statistical significance that COPD patients with dislipidemia had less frequent exacerbations compared to patients without dislipidemia (HR 0.92; *p* = 0.067). This observation seems to be in line with findings by Ingebrigtsen et al*.,* who recently reported that statin use for treatment of dislipidemia was associated with reduced odds of exacerbations in individuals with COPD \[[@CR22]\] and findings by Chan et al. that hyperlipidemia in COPD was associated with decreased incidence of pneumonia and mortality in retrospective analyses of health insurance data \[[@CR23]\]. Intuitively, the observed lower risk of frequent exacerbations in COPD patients with comorbid diabetes might be sought in GPs' reluctance to prescribe oral corticosteroids in these patients because the impact this may have on glucose levels, but a survey among Dutch GPs showed that most of them do not adjust treatment of exacerbations to the presence of diabetic comorbidity \[[@CR24]\]. Gastroesophageal reflux disease (OR = 1.25 (95% CI 1.03--1.50) in our analyses) was recognized as a significant predictor of acute exacerbations of COPD in a recent review by Lee et al \[[@CR25]\]. A relationship between prostate disorders and exacerbations has not been described in the literature, but might be related to use of inhaled anticholinergics.

Strengths and limitations {#Sec14}
-------------------------

A strength of this study is the inclusion of \>14 thousand COPD patients from a real-life, unbiased primary care setting. However, the main strength is not so much the uniqueness or even the size of our dataset. Other existing general practice databases essentially contain the same, or even more detailed data regarding diagnoses and medication prescriptions, \[[@CR26]--[@CR29]\] but the meticulousness with which we have looked at ALL chronic comorbidity, including recurrent episodes of conditions that are not necessarily chronic in all patients, seems unprecedented. Moreover, other existing databases with real-life general practice COPD data mainly stem from the UK and Denmark, and now there is also one available from the Netherlands. We intentionally applied minimal exclusion criteria in order to maximize generalizability of the results. Another strength is the wide range of chronic comorbidities investigated, summing up to a total of 82 conditions. Apart from all commonly known chronic comorbid diseases, we also included several recurrent diseases (i.e., depression, anxiety, anemia, dyspepsia, urinary tract infection) and applied criteria to define their chronicity based on disease specific guidelines (see [Appendix 1](#Sec17){ref-type="sec"}). Inclusion of patients with recurrent diseases seems relevant when studying risk factors for COPD exacerbations, but has not been done in previous studies.

Our study was based on patients' medical records in general practice. Limited agreement between medical record-based and objectively identified comorbidities of COPD \[[@CR30]\] and undiagnosed comorbidity in COPD patients is common \[[@CR18], [@CR31]\]. This may have resulted in underestimation of the presence of comorbidity in our study population. The use of real-life data presents limitations, for instance the fact that patients' smoking history and lung function could not be included because this information is not consistently and uniformly documented in general practice medical records. We chose to limit the analyses to comorbidities with a relatively high (i.e., ≥5%) prevalence. This may mean that comorbidities that are related to increased exacerbation risk but have a low prevalence rate in the COPD patient population were missed.

We defined an exacerbation as an oral corticosteroid prescription, which is the recommended treatment for acute exacerbations in Dutch COPD guidelines \[[@CR15]\]. Consequently, mild exacerbations treated with bronchodilators only are not included in our analyses. Oral steroid prescriptions during GP out-of-office hours, emergency department visits and hospitalizations, and prescriptions by pulmonary specialists may not always have been included for all patients, as these are not automatically added to patients' medical records in all electronic patient record systems. Because there is no international consensus about a definition that discriminates relapse of an earlier exacerbation from a new one, our (arbitrary) choice to use an interval of ≥14 days since the end date of the previous oral steroid prescription may have led to under- or overestimation of the number of exacerbations. Unfortunately, the rather crude prescription information did not allow us to look at the impact of comorbidities on the duration or progression of exacerbations. Although observational studies such as ours lack the rigorous internal validity that is typical for randomized controlled trials, they provide valuable insight into comorbidity prevalence in COPD and its relation with an important outcome, i.e., exacerbations. As such, our findings should be considered in conjunction with those arising from other study designs, including randomized trials.

Clinical implications {#Sec15}
---------------------

Better knowledge about the role that comorbidity plays in COPD exacerbation risk may contribute to lower exacerbation rates in COPD patients through patient-tailored and systems medicine approaches. In turn, reduction of exacerbations may improve patients' quality of life and prevent disability, hospitalizations, and mortality. A challenge for researchers is to find ways to enable physicians to take comorbidity into account when assessing COPD patients' exacerbation risk. Putcha et al*.* developed a simple score that includes 14 comorbidities, where one point increase in comorbidity count was associated with 21% higher exacerbation risk \[[@CR9]\]. However, their comorbidity score does not include comorbidities such as asthma, lung cancer and depression, while our results indicate that these comorbidities are also related to exacerbation risk. Neither does Putcha's score take differences in exacerbation risk for different comorbidities into account. This highlights the importance of including a wide range of comorbid chronic conditions like we did in our study.

Beside Putcha's comorbidity score, several prognostic indices to support COPD patient care have been developed, \[[@CR32]\] most of them predicting prognosis in terms of mortality or hospitalization. Only few indices predict exacerbation risk and only one (the DOSE index \[[@CR33]\]) has been developed and validated in primary care \[[@CR34]\]. Comorbidity is not included in the existing prognostic indices, with the exception of the COTE index, which assesses mortality and not exacerbation risk \[[@CR10], [@CR11]\]. Our results may contribute to the development of a prognostic index that connects comorbidities with exacerbation risk to identify patients at highest risk, thereby potentially reducing disease progression.

Conclusion {#Sec16}
==========

We have confirmed that many patients with COPD are affected by chronic comorbidities. Several highly prevalent as well as cardiopulmonary comorbidities appear to be independently associated with the risk of suffering from frequent exacerbations in our unbiased primary care patient population. Apart from clinical COPD guidelines advising that comorbidities should be diagnosed and treated appropriately, insight in patients' comorbidity patterns could also be used to identify those that are more likely to suffer from frequent exacerbations. Further research is needed to assess opportunities of implementation of this knowledge in routine care, so that patient-centered COPD care that also takes comorbidity into account can become the standard. Ultimately this may contribute to reducing disease progression and reduce the significant burden that COPD and its exacerbations puts on patients and healthcare systems.

Appendix 1 {#Sec17}
==========

Table 6List of 82 comorbidities included in comorbidity selection, sorted by prevalence (%) in the study populationComorbiditiyPrevalence (%)DiagnosisICPC codeInclusion criteriaHypertension35.2HypertensionK86, K87ICPC code before 1-1-12Coronary heart disease19.2Myocardial infarction/other ischemic heart diseaseK75, K76, K76.02, K76.01ICPC code before 1-1-12Angina PectorisK74, K74.01, K74.02ICPC code before 1-1-12Osteoarthritis17.6Artrose/spondylose wervelkolomL84, L84.01, L84.02ICPC code before 1-1-12GonartroseL90ICPC code before 1-1-12CoxartroseL89ICPC code before 1-1-12Osteoarhritis, otherL91ICPC code before 1-1-12Diabetes17.3DM1, DM2T90, T90.01, T90.02ICPC code before 1-1-12Peripheral vascular disease14.3AtheroscleroseK91ICPC code before 1-1-12Intermittent claudication/Raynaud/BuergerK92, K92.01, K92.02, K92.03ICPC code before 1-1-12Other disease cardiovascular systemK99, K99.01, K99.02, K 99.03, K99.04, K99.05, K99.06ICPC code before 1-1-12Blindness & low vision13.8(Diabetic/hypertensive) retinopathyF83, F83.01, F83.02ICPC code before 1-1-12MaculadegeneratieF84ICPC code before 1-1-12Blindness/amblyopiaF94ICPC code before 1-1-12CataractF92, F92.01ICPC code before 1-1-12Dyspepsia, Gastroesophageal reflux (GERD)12.6Stomach ulcerD86.01ICPC code before 1-1-12 AND (recode OR connection to episode) 12 months after first ICPC \[[@CR35]\]Duodenal ulcerD85ICPC code before 1-1-12 AND (recode OR connection to episode) 12 months after first ICPC \[[@CR35]\]Peptic ulcer, otherD86ICPC code before 1-1-12 AND (recode OR connection to episode) 12 months after first ICPC \[[@CR35]\]Oesophagus reflux with and without oesophagitisD87, D87.01, D87.02, D84, D84.02, D84.03ICPC code before 1-1-12 AND (recode OR connection to episode) 12 months after first ICPC \[[@CR35]\]Dislipidemia11.5Hypercholesterolemia/hypertriglyceridemiaT93, T93.01, T93.02, T93.03, T93.04ICPC code before 1-1-12Stroke & transient ischaemic attack9.7TIA (transient ischemic accident)K89ICPC code before 1-1-12CVA (cerebrovascular accident)K90, K90.01, K90.02, K90.03ICPC code before 1-1-12Chronic kidney diease9.5Renal dysfunctionU99, U99.01ICPC code before 1-1-12Asthma8.5AsthmaR96, R96.01, R96.02ICPC code before 1-1-2012 AND (recode OR connection to episode) 24 months after first ICPC code \[[@CR36]\]Hearing loss8.1DeafnessH84, H86, H85ICPC code before 1-1-12OtosclerosisH83ICPC code before 1-1-12Heart failure7.9(congestive) heart failureK77, K77.01, K77.02ICPC code before 1-1-12Pulmonary heart diseaseK82ICPC code before 1-1-12Atrial fibrillation7.5Atrial fibrillation/flutterK78ICPC code before 1-1-12Skin cancer6.3Skin cancerS77.01, S77.02, S77.03, S77.04, S77ICPC code before 1-1-12Osteoporosis/osteopenia6.3Osteoporosis/osteopenieL95, L95.01, L95.02ICPC code before 1-1-12Depression5.6Depressive disorderP76, P76.01ICPC code before 1-1-2012 AND (recode OR connection to episode) 24 months after first ICPC code \[[@CR37], [@CR38]\]Thyroid disorder5.6HypothyroidismT86ICPC code before 1-1-12HyperthyroidismT85ICPC code before 1-1-12Psoariasis4.6PsoriasisS91ICPC code before 1-1-12Obesity4.4AdipositasT82ICPC code before 1-1-12Anxiety4.3Somatoform disorderP75ICPC code before 1-1-2012 AND (recode OR connection to episode) 24 months after first ICPC code \[[@CR39]\]PhobiaP79.01ICPC code before 1-1-2012 AND (recode OR connection to episode) 24 months after first ICPC code \[[@CR39]\]Anxiety disorderP74, P 74.01, P74.02ICPC code before 1-1-2012 AND (recode OR connection to episode) 24 months after first ICPC code \[[@CR39]\]Obsessive - compulsive disorderP79.02ICPC code before 1-1-2012 AND (recode OR connection to episode) 24 months after first ICPC code \[[@CR39]\](chronic) functional somatic symtomsP01, P78ICPC code before 1-1-2012 AND (recode OR connection to episode) 24 months after first ICPC code \[[@CR39]\]Post traumatic stress disorderP02.01ICPC code before 1-1-2012 AND (recode OR connection to episode) 24 months after first ICPC code \[[@CR39]\]Eczema4.1Atopic dermatitisS87ICPC code before 1-1-12Heart valve disease3.9Heart valve diseaseK83, K83.01, K83.02ICPC code before 1-1-12Heart valve disease (rheumatic)K71.02ICPC code before 1-1-12Diverticular disease of intestine3.9Colonic diverticula, diverticulitisD92ICPC code before 1-1-12Alcohol problems3.9Chronic alcohol abuseP15, P15.01, P15.02, P15.03, P15.04, P15.05, P15.06ICPC code before 1-1-12Rheumatoid arthritis, other inflammatory polyarthropathies & systemic connective tissue disorders3.7Rheumatoid arthritis/ankylosing spondylarthritisL88.01, L88.02, L88ICPC code before 1-1-12Bronchiectasis/chronic bronchitis2.8Bronchiectasis/Chronic bronchitisR91.02, R91, R91.01ICPC code before 1-1-12Irritable bowel syndrome2.8Irritable bowel syndromD93ICPC code before 1-1-12Venous insufficiency2.4Venous insufficiencyK99.04ICPC code before 1-1-12Varicose ulcerS97, S97.01ICPC code AND (recode OR connection to episode) 3 months after first ICPC code \[[@CR40]\]Pulmonary cancer2.4lung/bronchial cancerR84ICPC code before 1-1-12Recurrent urinary tract infection2.3Urinary tract infection, chronic/recurrentU71, U71.01, U71.02ICPC code AND (recode OR connection to episode) ≥3 times/year in 2011, 2012, 2013. Years start with 1e ICPC code. Minimal 8 weeks between each episode \[[@CR41]\]Breast cancer2.3Breat cancerX76, X76.01ICPC code before 1-1-12Glaucoma2.2Glaucoma/verhoogde oogboldrukF93, F93.01, F93.02, F93.03, F93.04ICPC code before 1-1-12Gout2.0GoutT92ICPC code AND (recode OR connection to episode) ≥3 times/year in 2011, 2012, 2013. Years start with 1e ICPC code. Minimal 22 days between each episode \[[@CR42]\]Prostate cancer1.9Prostate cancerY77ICPC code before 1-1-12Dementia1.7Alzheimer\'s disease/Senil dementia/Alzheimer/Multi-infarct dementiaP70.01, P70, P70.02ICPC code before 1-1-12Colorectal cancer1.7Colon cancerD75ICPC code before 1-1-12Rectal cancerD75ICPC code before 1-1-12Epilepsy1.4EpilepsyN88ICPC code before 1-1-12Bladder cancer1.3Bladder cancerU76ICPC code before 1-1-12Sleep apnea syndrome1.2Sleep apnea syndromeP0601ICPC code before 1-1-12Underfeeding/vitamine deficiency1.2Underfeeding/vitamine deficiencyT91, T05ICPC code before 1-1-12 AND (recode OR connection to episode) 12 months after first ICPCInflammatory bowel disease1.2Crohn\'s disease/Ulcerative colitisD94, D94.01, D94.02ICPC code before 1-1-12Personality disorder1.2Personality disorderP80, P80.01, P80.02ICPC code before 1-1-12Prostate disorders1.2Prostatic hyperplasia/hypertrophyY85ICPC code before 1-1-12Other chronic pulmonary disease1.1Pulmonary tuberculosisR70ICPC code before 1-1-12PneumoconiosisR99.06ICPC code before 1-1-12SarcoidosisR83.02ICPC code before 1-1-12Chronic liver disease1Cirrose/steatoseD97, D97.04, D97.05ICPC code before 1-1-12Genitourinary cancer, other0.9Genitourinary cancer, otherU75, U77, X77, Y78, Y78.01, Y78.03ICPC code before 1-1-12Blood(forming organs) and lymphatics disorder0.8Benign non specified neoplasm blood/lymphatic disorderB75ICPC code before 1-1-12 AND (recode OR connection to episode) 12 months after first ICPC \[[@CR43]\]HaemophiliaB83.01ICPC code before 1-1-12Congenital blood/lymphatic disorderB79ICPC code before 1-1-12Purpura/coagulation disorders/abnormal trombocytesB83, B83.02, B83.06ICPC code before 1-1-12Schrizophrenia/non-organic psychosis/bipolar disorder0.8SchizophreniaP72ICPC code before 1-1-12Psychosis non specifiedP98ICPC code before 1-1-12BipolarP73.02ICPC code before 1-1-12Migraine0.8MigraineN89ICPC code before 1-1-12 AND (recode OR connection to episode) 12 months after first ICPC \[[@CR44]\]Cancer oropharynx, oesophageal, stomach0.8Cancer of the mouth/pharynxD77.02, D77.03ICPC code before 1-1-12Oesophageal cancerD77.01, D77ICPC code before 1-1-12Cancer of stomachD74ICPC code before 1-1-12Other psychoactive substance misuse0.7Substance abuseP19, P19.01, P19.02ICPC code before 1-1-12Parkinson\'s disease0.6Parkinson\'s diseaseN87.01, N87ICPC code before 1-1-12Other chronic skin disease/neoplasm (sub)cutis0.6Neoplasm cutis, subcutis non specifiedS80, S80.01, S81, S83, S83.01, S83.02ICPC code before 1-1-12Vitiligo/lichen planusS99.04, S99.06ICPC code before 1-1-12Viral hepatitis0.6Hepatitis BD72.02, D72.04ICPC code before 1-1-12Hepatitis CD72.03, D72.05ICPC code before 1-1-12HepatitisD72ICPC code before 1-1-12Uterine cervical cancer0.5Uterine cervical cancerX75ICPC code before 1-1-12Learning disability'/Mental retardation0.4Mental retardationP85ICPC code before 1-1-12Specified learning problemsP24. P24.01, P24.02, P24.03ICPC code before 1-1-12Laryngeal/throat cancer0.4Laryngeal/troat cancerR85ICPC code before 1-1-12Hodgkin disease0.4Hodgkin diseaseB72, B72.01, B72.02ICPC code before 1-1-12Carcinoma, other0.4Carcinoma, otherD77.04, T71, W72, L71, L71.01ICPC code before 1-1-12Chronic sinusitis0.3Chronic sinusitisR75.02ICPC code before 1-1-12Acute SinusitisR75.01 en R75ICPC code AND (recode OR connection to episode) ≥3×/year in 2011, 2012, 2013. Years start with 1e ICPC code. Minimal 29 days between each episode. \[[@CR45]\]Glomerulonephritis/nephrosis0.3GlomerulonephritisU88ICPC code before 1-1-12Congenital cardiovascular anomaly0.2Congenital cardiovascular anomalyK73, K73.01, K73.02ICPC code before 1-1-12Leukaemia0.2LeukaemiaB73ICPC code before 1-1-12Lymphoma/multiple myeloma/other blood cancer0.2Lymphoma/multiple myeloma/other blood cancerB74.01, B74ICPC code before 1-1-12Anaemia0.1Pernicous/folic acid anaemiaB81, B81.01, B81.02ICPC code before 1-1-12 AND (recode OR connection to episode) 12 months after first ICPC \[[@CR43]\]Haemolytic anaemiaB78, B78.01, B78.02, B78.03ICPC code before 1-1-12Anorextia or bulimia0.1Anorexia nervosaT06, T06.01, T06.02ICPC code before 1-1-12Coeliakie0.1CoeliakieD99.06ICPC code before 1-1-12Endometrial cancer0.1Endometrial cancerX77.01ICPC code before 1-1-12Metastases; unknown origin0.1Metastases; unknown originA79ICPC code before 1-1-12Multiple sclerosis0.1MS (multiple sclerosis)N86ICPC code before 1-1-12Ovarian cancer0.1Ovarian cancerX77.02ICPC code before 1-1-12Pancreatic cancer0.1Pancreatic cancerD76ICPC code before 1-1-12Testis cancer0.1Testis cancerY78.02ICPC code before 1-1-12Brain cancer (recall: Nervous system cancer)0Brain cancer (recall: Nervous system cancer)N74ICPC code before 1-1-12HIV/AIDS0HIV; AIDSB90, B90.01, B90.02ICPC code before 1-1-12
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Table 7List of comorbidity categoriesCategories of chronic diseaseDiseaseCardiovascularHypertensionCoronary heart diseaseCongenital cardiovascular anomalyHeart failureStroke & transient ischaemic attackAtrial fibrillationHeart valve diseaseVenous insufficiencyPeripheral vascular diseaseRespiratoryCOPDAsthmaSleep apnea syndromeChronic sinusitisOther chronic pulmonary diseaseBronchiectasis/chronic bronchitisMental HealthDepressionAnxiety disorderAlcohol problemsOther psychoactive substance misuseSchrizophrenia/non-organic psychosis/bipolar disorderAnorextia or bulimiaPersonality disorderLearning disability'/Mental retardationMusculoskeletalRheumatoid arthritis, other inflammatory polyarthropathies & systemic connective tissue disordersGoutOsteoporosis/osteopenieOsteoarthritisEye and EarHearing lossGlaucomaBlindness & low visionUrogenital (Male and female)Chronic kidney dieaseGlomerulonephritis/nephrosisRecurrent urinary tract infectionProstate disordersSkinEczemaPsoriasisOther chronic skin disease/neoplasm (sub)cutisDigestiveDiverticular disease of intestineDyspepsia, Gastroesophageal refluxIrritable bowel syndromInflammatory bowel diseaseCoeliakieChronic liver diseaseEndocrine, metabolic and nutritionUnderfeeding/vitamine deficiencyDiabetesDislipidemiaObesityThyroid disorderNeurologicalDementiaEpilepsyMigraineParkinson\'s diseaseMultiple sclerosisBlood(forming organs) and LymphaticsAnaemiaBlood (forming organs) and lymphatics disorderInfectiousViral hepatitisHIV/AIDSNon-pulmonary cancerTestis CancerCancer oropharynx, oesophageal, stomachCancer ColorectalPancreatic cancerLaryngeal/troat cancerBreast cancerOvarian cancerEndometrial cancerUterine cervical cancerProstate cancerBladder cancerGenitourinary cancer, otherBrain cancer (recall: Nervous system cancer)Hodgkin diseaseLeukaemiaLymphoma/multiple myeloma/other blood cancerMetastases; unknown originCarcinoma, otherSkin cancerPulmonary cancerPulmonary cancer
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Table 8Baseline characteristics of the initial population of all COPD patients, the patients who were lost to follow-up, and the patients with full follow-upAll COPD patients\
(*n*=16,427)Patients lost to follow-up\
(*n*= 1,824)Patients with full follow-up (study population)^a^\
(*n*=14,603)Patient characteristics Sex, male, n (%)8,682 (52·9)933 (51·2)7,749 (53·1) Age at study baseline, years; mean (SD; range)66·9 (11·6; 40--111)70·1 (12·0; 40--111)66·5 (11·5; 40--110)^‡^Full dataset available (censored data), n (%) Full data available14,603 (88·7) Deceased541 (3·0)541 (29·7)N/A Moved223 (1·3)223 (12·2)N/A Nursing home36 (0·2)36 (2·0)N/A Unknown1024 (6·2)1024 (56·1)N/AComorbidity data Number of comorbid diseases^b^, mean (SD; range)3·0 (2·3;0--20)3·4 (2·5; 0--16)3·0 (2·3;0--20)^‡^Number of comorbid diseases categories^b^, n (%) 01,951 (11·9)174 (9·5)1,777 (12·2) 1 or 25,891 (35·9)586 (32·1)5,305 (36·6) 3 or 44,797 (29·2)539 (29·6)4,258 (29·2) 5 and more3,788 (23·1)525 (28·8)3,263 (22·3)^‡^Exacerbations dataNumber of exacerbations, mean (SD; range)0·72 (1·5;0--15)^c^0·46 (1·0;0--11)^c^0·75 (1·5;0--15)*SD* standard deviation, *N/A* not applicable^\*^ *p*\<0.05, ^†^ *p*\<0.01, ^‡^ *p*\<0.001^a^ *p*-values displayed are calculated for the difference between patients lost to follow-up *versus* patients with full follow-up. Chi-square tests for categorized variables and independent t-tests for continuous variables. *p*\<0·05 was considered statistically significant^b^Presence of any type of comorbid disease was assessed at study baseline, i.e. 1 January 2012^c^Mean number of exacerbations during the study period, 1 January 2012 -- 31 December 2013. For the columns 'all COPD patients' and 'Patients lost to follow-up' these rates cannot be converted into annual rates because of incomplete observation time in the patients who were lost to follow-upBaseline characteristics of the study population grouped by low (\<2/year) *versus* high (≥2/year) exacerbation rate are reported in Table [1](#Tab1){ref-type="table"}

ATC

:   Anatomical therapeutic chemical

CKD

:   Chronic kidney disease

COPD

:   Chronic obstructive pulmonary disease

GERD

:   Gastroesophageal reflux disease

GP

:   General practitioner

ICPC

:   International classification of primary care

N/A

:   Not applicable

OR

:   Odds ratio

SD

:   Standard deviation

TIA

:   Transient ischemic attack

UK

:   United Kingdom

US

:   United States
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